Active Substance: Sorafenib (as tosylate, micronized).
Overview
Welcome to Dwaey, specifically on NEXAVAR 200mg page.
This medicine contains an important and useful components, as it consists of
Sorafenib (as tosylate, micronized)is available in the market in concentration
Sorafenib
Interrupt teatment if patient develops cardiac infarction, ischaemia and/or bleeding fatalities. Regular monitoring of BP, CBC and platelet is recommended. Monitor INR in patients who are on treatment with warfarin. Adequate contraception should be used during and for at least 2 wk after stopping treatment. May need to discontinue treatment if severe or persistent hypertension occurs. Lactation: not known whether distributed in breast milk, discouraged
Renal cell carcinoma, Hepatocellular Carcinoma, Thyroid Cancer
Hypersensitivity
>10% Thrombocytopenia (12-46%),Anemia (44%),Diarrhea (43%),Rash/desquamation (40%),Fatigue (37%),Abd pain (31%),Hand-foot skin reaction (30%),Weight loss (30%),Anorexia (29%),Alopecia (27%),Nausea (24%),Lymphopenia (23%),Neutropenia (18%),Hemorrhage (15-18%),Hypertension (9-17%),Vomiting (16%),Constipation (15%),Neuropathy (13%),Dry skin (11%) 1-10% Headache (10%),Joint pain (10%),Congestive heart failure, MI (1.9%),QT prolonation (rare) <1% Acute renal failure,Angioedema and arrhythmia may occur,Bone pain reported Frequency Not Defined Stevens-Johnson Syndrome,Hyperthyroidism,Interstitial lung disease Potentially Fatal: Bleeding fatalities. Hypertensive crisis.
4
Sorafenib inhibits cell surface and intracellular kinases to reduce proliferation of tumour cells.
Inducers of isoenzyme CYP3A4 e.g. carbamazepine, dexamethasone, phenobarbital, phenytoin, rifampicin may decrease sorafenib plasma concentration. Coadmin with sorafenib may increase the plasma concentration of doxorubicin and irinotecan.
Information not available